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Ex Vivo Recapitulation of Trauma-Induced Coagulopathy and Preliminary
Assessment of Trauma Patient Platelet Function Under Flow Using Microfluidic
Technology
Abstract
Background: Relevant to trauma induced coagulopathy (TIC) diagnostics, microfluidic assays allow
controlled hemodynamics for testing of platelet and coagulation function using whole blood.
Methods: Hemodilution or hyperfibrinolysis was studied under flow with modified healthy whole blood.
Furthermore, platelet function was also measured using whole blood from trauma patients admitted to a
Level 1 Trauma center. Platelet deposition was measured with PPACK-inhibited blood perfused over
collagen surfaces at a wall shear rate of 200 s-1, while platelet/fibrin deposition was measured with corn
trypsin inhibitor (CTI)-treated blood perfused over TF/collagen.
Results: In hemodilution studies, PPACK-treated blood displayed almost no platelet deposition when
diluted to 10% Hct with saline, platelet poor plasma (PPP), or platelet rich plasma (PRP). Using similar
dilutions, platelet/fibrin deposition was essentially absent for CTI-treated blood perfused over TF/
collagen. To mimic hyperfibrinolysis during trauma, exogenous tPA (50 nM) was added to blood prior to
perfusion over TF/collagen. At both venous and arterial flows, the generation and subsequent lysis of
fibrin was detectable within 6 min, with lysis blocked by addition of the plasmin inhibitor, [epsilon]aminocaproic acid. Microfluidic assay of PPACK-inhibited whole blood from trauma patients revealed
striking defects in collagen response and secondary platelet aggregation in 14 of 21 patients, while
platelet hyperfunction was detected in 3 of 20 patients.
Conclusions: Rapid microfluidic detection of (i) hemodilution-dependent impairment of clotting, (ii) clot
instability due to lysis, (iii) blockade of fibrinolysis, or (iv) platelet dysfunction during trauma may provide
novel diagnostic opportunities to predict TIC risk.
Level of Evidence: Level IV
Study type: Diagnostic Test
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BACKGROUND
Trauma is the leading cause of death in people under the age of 36 years old (1). Many severely
injured patients exhibit trauma induced coagulopathy (TIC), a hemorrhagic state that accounts for
40% of trauma deaths (1). TIC is multifactorial and associated with tissue injury, inflammation,
shock, hemodilution, acidosis, hypoxia, and hypothermia (1). Tissue injury and shock result in
hyperfibrinolysis due to the acute release of tissue plasminogen activator (tPA) from endothelial
cells. Systemic fibrinolysis results in fibrinogen consumption and limits clot formation and
stability at the site of vascular injury, resulting in increased bleeding risk (2). Furthermore, blood
loss followed by resuscitation with colloids or packed red blood cells (PRBCs) leads to the
hemodilution of clotting factors.

Most research in TIC has focused on coagulation factors and proteases, with the role of platelet
function during trauma not as well studied (3,4). Platelet function studies of trauma patients have
been difficult to implement due to the technical complexities of current platelet function tests.
Although recent advances in platelet aggregometry and thromboelastography (TEG) have enabled
important studies of platelet function and clot strength in trauma patients (5–9). These techniques,
however, are closed systems lacking flow or presenting poorly defined flow fields.

Microfluidic systems are open systems where blood flows over a zone of defined procoagulant
surface, thereby recreating the unique spatial and compositional attributes of blood clotting found
in vivo (10). Microfluidic technology in conjunction with micropatterning techniques enable low
volume and high throughput testing of platelet function and fibrin generation over a range of
physiological shear stresses (11–15). Microfluidic whole blood assays have been previously used
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to evaluate platelet and clotting function in hemophiliacs and healthy donors taking antiplatelet
therapeutics (10,16–18).

In regards to current resuscitation strategies, the administration of PRBCs with or without fresh
frozen plasma (FFP) and the optimal FFP:PRBCs ratio remain active areas of investigation (19).
Prospective studies have shown that platelets may serve as the third component of resuscitation
strategy (19–22). PRBC administration not only increases hemoglobin, but also contributes
biorheologically by driving platelet margination towards the vessel wall.

In this study, we applied microfluidic technology to investigate resuscitation-driven
hemodilution, hyperfibrinolysis, and plasmin-inhibitor therapy, all topics relevant to TIC risk and
treatment. Additionally, we evaluated platelet function under flow using whole blood from
trauma patients.
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METHODS
Microfluidic evaluation of hemodilution and hyperfibrinolysis
Following approval from the Internal Review Board approval at the University of Pennsylvania,
healthy donors (n = 15) were recruited to donate whole blood using standard phlebotomy
techniques. Donors were required to refrain from all oral medications for 7 days and abstain from
alcohol for 48 hours prior to donation. Blood was drawn into corn trypsin inhibitor (CTI,
Haematologic Technologies, Essex Junction, VT, 40 µg/ml final concentration) or FPRchloromethylketone (PPACK, Haematologic Technologies, Essex Junction, VT, 100 µM final
concentration). CTI inhibits the contact pathway for studies of surface-triggered coagulation while
PPACK inhibits thrombin generation in order to examine platelet function in the absence of
thrombin in vitro. Blood samples were treated with fluorescently conjugated anti-CD61a antibody
(clone VI-PL2, Becton Dickson, Franklin Lakes, NJ, 0.125 µg/ml final concentration) to label
platelets and fluorescently conjugated fibrinogen (Invitrogen, Life Technologies, Carlsbad, CA,
75 µg/ml) to label fibrin(ogen) 5 min prior to initiation of flow assays. All healthy donor
microfluidic experiments were completed within 45 min of phlebotomy.

Microfluidic fabrication methods and device specifications were previously described (11,17,23).
Microfluidic channels ran perpendicularly over a 250 µm wide strip of patterned equine fibrillar
collagen type I (Chronopar, Chronolog) or Tissue factor (TF) bearing collagen type I surfaces
(Dade Innovin, Siemens Healthcare USA, Malvern, PA). Epifluorescent microscopy and image
acquisition were performed in real-time as previously described (10,17). Dilution of the hematocrit
to simulate resuscitation-induced hemodilution was achieved with exogenous addition of HEPES
buffered saline (HBS, 20 mM HEPES, 160 mM NaCl, pH 7.5), donor specific platelet poor plasma
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(PPP) or platelet rich plasma (PRP). Isolation of PRP or PPP was previously described (17,24).
HBS, PPP or PRP was added in 1:3, 1:1, 3:1 ratio to whole blood to obtain Hct levels of 30%,
20%, 10% respectively 5 min prior to initiation of the flow assay. Fibrinolysis was promoted by
exogenously adding 10X stock solutions of tPA (abcam, Cambridge, MA, 0-50 nM). Blood
samples were perfused at an initial venous wall shear rate of 200 s-1 or arterial wall shear rate of
1222 s-1 in a previously designed pressure relief mode for 20 min (12). Platelet and fibrin
accumulation analysis was completed as previously described (17).

Microfluidic Assessment of Trauma Patient Platelet Function
Following Institutional Review Board approval, blood was collected from trauma patients (n = 20)
who had sustained injuries requiring evaluation at the Hospital of University of Pennsylvania
(HUP) Level 1 Trauma Center. Exclusion criteria included failure to obtain an initial blood draw
and death within 24 hr of admission. Patient demographics, clinical laboratory test results, and
outcomes were recorded (Table 1). All trauma patients had Hct levels and platelet counts within
physiologic ranges (Table 1). All clinical laboratory tests were obtained at the same time as the
microfluidic assessment of trauma patient platelet function. All trauma patient samples were
collected within one hour of injury. A blood sample was drawn upon patient arrival using 21-guage
or larger needle into a 10 ml plastic syringe (Becton Dickson, Franklin Lakes, NJ) containing no
anticoagulant. Blood samples were aliquoted into vacationers for clinical assays and residual blood
was transferred into a single vacutainer containing 100 µM PPACK. The effects of this collection
method and the delay between phlebotomy and inhibition by PPACK (average ~ 3 min) were
assessed and found to have negligible effects on platelet activation and thrombin generation
(Supplemental Fig. 6 & Fig. 7).
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PPACK treated blood samples were treated with fluorescently conjugated anti-CD61a antibody
(clone VI-PL2, Becton Dickson, Franklin Lakes, NJ, 0.125 µg/ml final concentration) to label
platelets and anti-human CD62P (P-Selectin) antibody (BioLegend, San Diego, CA, 4 µg/ml final
concentration) to stain for P-Selectin. Blood samples were subsequently treated with either HBS
or 100X stock solutions of the indicated antagonists. MRS 2179 (2'-deoxy-N6-methyladenosine
3', 5'-bisphosphate ammonium salt (MRS 2179, Tocris Bioscience, Minneapolis, MN), SNitrosoglutathione (GSNO, Santa Cruz Biotechnology, Dallas TX), and iloprost (Tocris
Bioscience) were the antagonists used and dissolved at 0.1 mM, 10 mM, 0.2 mM in HBS
respectively. Whole blood perfusion in microfluidic devices started within 10 min of blood
collection in constant flow mode at 100 s-1.

Statistical Significance Analysis
Statistical significance was assessed using a two-tailed unpaired Student's t-test. Data sets were
considered significantly different from each other if the calculated p-value < 0.05. Exact p-values
are reported in the results where p > 0.001, otherwise p < 0.001 is denoted.
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RESULTS
Hemotocrit reduction: dilution reduces platelet deposition on collagen (no thrombin) and plateletfibrin accumulation on TF/collagen.
Our healthy volunteer study population had a mean age 26.2 ± 1.52y (10M/5F). The effect of
hematocrit dilution on platelet deposition was evaluated by ex vivo dilution of healthy whole blood
with either saline, PPP, or PRP (Supplemental Fig. 1). In the absence of thrombin with PPACKtreated whole blood at 200 s-1, platelet deposition was strongly inhibited by hemodilution with
saline (p < 0.001), PPP (p < 0.001), or PRP (p < 0.001: 10 & 20% Hct, p = 0.01: 30% Hct) (Fig.
1A,C,E). As expected in the flow assay over collagen, fibrin generation was dependent on
thrombin production and was negligible in PPACK-inhibited whole blood in the absence of
surface-patterned TF on collagen (Fig. 1B, D, F).

Similarly, in the presence of surface-triggered coagulation (Fig. 2), we detected significant
decreases in platelet accumulation for all lowered Hct levels when whole blood was diluted with
saline (p < 0.001: 10 & 20% Hct, p = 0.0154: 30% Hct), PPP (p < 0.001: 10 & 20% Hct, p = 0.002:
30% Hct or PRP (p < 0.001: 10% Hct, p = 0.0035: 20% Hct, p = 0.0316: 30% Hct) (Fig. 2A, C,
E). Total fibrin accumulation at lower Hct levels was also significantly reduced when whole blood
was supplemented with saline (p < 0.001: 10, 20 & 30% Hct) or PPP (p < 0.001: 10% Hct, p =
0.005: 20% Hct, p = 0.0064: 30% Hct) or PRP (p < 0.001: 10% & 20% Hct, p = 0.3576: 30% Hct)
to reduce Hct (Figure 2B, D). The reduced fibrin accumulation observed with reduced Hct cannot
be due to a reduction in coagulation factors since the concentration of coagulation proteins remains
constant when whole blood is diluted with PPP or PRP (as opposed to saline dilution). In this
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experiment, reduced platelet deposition was highly correlated with reduced fibrin production as
Hct was reduced, regardless of how Hct was lowered (Figure 2).

Exogenous tPA activates the lytic state at venous and arterial shear rates and promotes
hyperfibrinolysis
Following severe trauma and shock, injured endothelial cells release tPA systemically leading to
hyperfibrinolysis (1). To mimic this pathological mechanism, tPA was exogenously added to
whole blood (Supplemental Figure 1). At venous shear rates (200 s-1), exogenous addition of tPA
to whole blood had negligible effects on platelet deposition on TF bearing collagen surfaces under
flow (Figure 3A, B; ns). However, the rapid production of plasmin at the surface-patterned injury
site in conjunction with fibrin formation at 200 s-1 induced a 'lytic state' with 50 nM ex vivo tPA
addition. Total fibrin accumulation decreased 63.9 % by 10 min (Figure 3C; p = 0.0044). To
reverse the 'lytic state' and stop fibrinolytic activity under flow, we added the lysine analogue εaminocaproic acid (εACA) to inhibit plasmin activity. The inhibition of plasmin by εACA restored
total fibrin accumulation to levels comparable to control conditions but resulted in delayed fibrin
initiation (Figure 4C). At arterial shear rates (1222s-1), embolization occurred with tPA as
indicated by a drastic drop in the platelet signal by 12 min (Figure 4). The platelet signal continued
to fall approaching zero by the end of the 20 min assay (Figure 4B). Exogenous tPA addition
minimized total fibrin formation while treatment with εACA non-significantly increased platelet
deposition (p = 0.1024) and total fibrin accumulation (p = 0.1132) (Figure 4B, C). Interestingly,
in a few channels of the microfluidic assay at either venous or arterial wall shear rates, tPAmediated fibrinolysis was followed by destabilization of platelet deposits which then embolized
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downstream. This disruption of platelet rich thrombi from the patterned injury site was followed a
second round of platelet deposition and renewed fibrin generation (Supplemental Figure S4, S5)

Trauma patient platelet function tests: delayed platelet recruitment to collagen and attenuated
secondary aggregation
Our 20 trauma patient population had a mean age of 50.2 ± 22.84 and a median injury severity
score (ISS) of 7.5 with an interquartile range of 25. There were 15% penetrating injuries and 25%
brain injuries. Rapid platelet function testing of PPACK-inhibited whole blood from trauma
patients (n = 20) revealed a subpopulation of patients (14/20) with reduced platelet function upon
arrival to a Level 1 Trauma Center (Figure 5, Supplemental Figure S8). When compared to 7
healthy donors, 14 trauma patients were found to have significantly decreased total platelet
accumulation measured at 900 sec (Supplemental Figure S9; p < 0.001). We categorized these
subset of patients as 'loss of function'. Patients with statically significant increased total platelet
accumulation measured at 900 sec when compared to healthy donors were categorized as 'gain of
function' (Figure 5, Supplemental Figure S9) Visual inspection of platelet aggregates formed on
collagen surfaces indicate two loss of function phenotypes in trauma patients. The first loss of
function phenotype in trauma patients was characterized by platelets failing to adhere to the
collagen surface indicative of dysfunctional platelet glycoprotein VI (GPVI) (Figure 5B, C, E,
K). In a second observed loss of function phenotype, platelet aggregate growth beyond the initial
monolayer of platelets was minimal or completely missing (Figure 5D, F-N). Platelet aggregates
tended to form above the initial monolayer of collagen-adherent platelets but were subsequently
washed downstream. Clots formed from these patients did not grow to full channel occlusion
during the duration of the 900 sec assay (Figure 5A, black arrow). This failure of secondary
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aggregation in these patients may be due to a lack of ADP or thromboxane A2 mediated clot
growth. Interestingly, 3 patients exhibited hyper-responsive platelet function in this microfluidic
assay with two patients forming occlusive clots within the first 400 seconds (Figure 5R-T).

Trauma patient platelets respond less to antagonism by MRS 2179 and iloprost but increased
sensitivity to inhibition by GSNO
To assess the various pathways that affect trauma platelet signaling under flow, we antagonized
platelet function in three different manners (Supplemental Figure S2). MRS 2179 was used to
potently inhibit the platelet ADP receptor, P2Y1. The addition of GSNO was used to stimulate
nitric oxide production ex vivo and iloprost was used to raise cyclic adenosine monophosphate
(cAMP) levels inside the platelet in order to reduce platelet aggregation. On average, trauma
patients with detectable baseline platelet function measured by platelet fluorescence responded to
all three forms of antagonism (Supplemental Figure S2C). Total platelet accumulation at 900 sec
was reduced 58.8%, 43.83% and 73.80 % by MRS 2179, GSNO, and iloprost respectively in
trauma patients (n = 17, 68 clots, p < 0.001) as compared to 79.2%, 15.2%, and 91.81% in healthy
donors (n = 6, 24 clots, p < 0.001) (Supplemental Figure S9). Interestingly, trauma patient platelet
function responded less to the addition of MRS 2179 or iloprost but was more strongly inhibited
by production of nitric oxide ex vivo (Supplemental Figure S9; MRS 2179: p = 0.003, Iloprost
or GSNO: p < 0.001).

A subpopulation of trauma patient platelets displayed decreased p-selectin expression under flow
P-selectin surface expression was also used as a marker for α-granule secretion and irreversible
platelet activation in our microfluidic assay (Supplemental Figure S3). A population of trauma
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patients (9/21) exhibited low p-selectin expression in the flow assay (data not shown) however,
when normalized against the platelet fluorescence signal, a single patient displayed a severe deficit
in p-selectin expression on a per platelet basis (Supplemental Figure S3B-D). The lack of pselectin expression in patient #9 may be indicative of low levels of platelet activation and potential
previous degranulation of platelets prior to microfluidic testing.

DISCUSSION
Trauma induced coagulopathy is a multi-faceted phenomenon that occurs in the combined setting
of shock, hemodilution, hypothermia, and tissue injury. With the use of microfluidic technology
we evaluated hemodilution and hyperfibrinolysis, two common mechanisms of TIC, in order to
understand how derangements in platelet deposition and fibrin formation contribute to altered
hemostasis. Hemodilution of healthy whole blood with saline, PPP, or PRP significantly reduced
platelet adhesion to collagen in the absence of surface-triggered coagulation at all lowered Hct
levels (Figure 1). Platelet deposition was also significantly decreased with this dilution scheme on
TF-bearing collagen surfaces (Figure 2). RBCs strongly influences platelet margination and
enhances platelet accumulation at the collagen or collagen/TF injury site in these assays. These
results indicate a significant role for RBCs in mediating the rapid platelet response required to seal
vessel injuries. Furthermore, RBCs have also been shown to release ADP thus promoting platelet
aggregation and can potentially sustain thrombin generation (25). This is could be another role in
which RBCs support platelet function and coagulation in our microfluidic assays. However, ADP
release from RBC is expected to be minimal under the venous flow conditions tested (Figure 2).

12

Furthermore, a second mechanism associated with TIC is increased fibrinolytic activity. Excessive
fibrinolysis impairs clot integrity and causes bleeding. We recapitulated this mechanism and
rapidly detected changes in fibrin accumulation and clot stability in microfluidic assays with
exogenous addition of tPA. We promoted a 'lytic state' under flow inducing fibrin lysis at venous
shear rates that was rescued with ex vivo εACA addition (Figure 3). At arterial shear rates, the
'lytic state' induced embolism as clots tore from the TF bearing collagen surfaces and washed
downstream (Figure 4). In rare cases, the 'lytic state' induced a consumptive coagulopathy with
complete fibrin lysis and disintegration of platelet aggregates followed by platelet re-adherence
and fibrin regeneration on the TF bearing collagen surface. This observed process depletes
platelets, clotting factors, and plasma proteins in the flowing blood. The deranged hemostasis
during hyperfibrinolysis we have recreated in the microfluidic assays mimics the coagulopathy of
traumatic brain injuries (26). Our results suggest that hyperfibrinolysis and excessive consumption
of clotting factors work synergistically during TIC. (Supplemental Figure S4, S5). Finally, we
were able to detect and quantify changes in fibrin generation and clot stability during this 'lytic
state' in <6 min, a time scale much faster than what is currently capable with TEG.

In clinical settings, conventional plasma-based assays are used to assess TIC instead of
microfluidic-based assays. The prothrombin time (PT), partial thromboplastin time (PTT), platelet
count, and fibrinogen levels are the most commonly used tests for monitoring coagulopathy
following trauma. These tests, however, examine only a single component of the hemostatic
process and fail to measure clot strength, fibrinolytic activity or platelet function. Furthermore,
while TEG with or without platelet mapping is more indicative of global hemostasis, the use of
FXII activator kaolin and citrated samples are major drawbacks with this technology. Kaolin
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activation of coagulation is non-physiologic as kaolin is not found in the body and citrate is known
to affect platelet αIIβIIIa integrin function. The fluid mechanics of TEG also fail to replicate the
hemodynamics of the vasculature. The oscillatory movement of a cup in a closed system cannot
generate the extraordinary platelet concentrations in a clot on the vessel wall. Furthermore, in TEG,
the moving cup is a closed system where platelet releasates and coagulation factors can accumulate
unhindered due to the lack of transport-induced washout of these components. Microfluidic
assessment of trauma patient function detected platelet function defects in < 5 min while a
complete TEG test may take upward to 60 min (27).

In whole blood microfluidic assays, on the other hand, platelet deposition and fibrin generation
must occur under well-controlled hemodynamic conditions and in the presence of convective
dilution of thrombin, soluble agonists, and plasma proteins. During these assays, the biorhelogic
phenomena present can either limit or augment local enzyme concentrations. In addition to
changes in the local enzyme concentrations, platelet receptor-ligand bonds must withstand the
hydrodynamic shear stress imparted by following blood. Thus whole blood microfluidic assays
provide a much more rigorous physiologic test of platelet function and fibrin generation not
captured by static clotting assays and TEG (28,29).

To the best of our knowledge, our results are the first real-time platelet function testing of whole
blood samples from trauma patients using microfluidic technology. One previous study by Jacoby
et al. has assessed platelet function following trauma using a platelet function analyzer (PFA-100)
with citrated whole blood. The PFA-100 is a cartridge-based flow system that aspirates citrated
whole blood in capillaries. It measures aperature closure time following blood clotting on a
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membrane coated with collagen/ADP or collagen/epinephrine. Their study reported decreased
closure times at initial trauma patient presentation indicating increased platelet function and
hypercoagulability. Contrary to the Jacoby et al. report, we observed noticeable decreases in
platelet adhesion to collagen and secondary platelet aggregation when we rapidly assessed platelet
function in trauma patients (n = 20) at 100s

-1

over collagen surfaces (Figure 5). Furthermore,

when comparing our microfluidic assay results to clinical patient data, we found no correlation
between platelet function and injury severity score (ISS), or platelet function and the diagnosis of
traumatic brain injury (TBI). All 14 patients displaying decreased platelet function had
physiological Hct levels and platelet counts. With respect to static plasma clotting assays, 13 of
the 14 patients with decreased platelet function were within the normal PTT reference range (20.834.4) (10). These results indicate that patient hematocrit levels, platelet counts, and plasma-based
clotting tests are largely inadequate in assessing the contribution of platelet function to acute
traumatic coagulopathy.

Interestingly, of the 7 patients that did require blood products post microfluidic testing, 4 patients
had decreased platelet function as initially assessed by whole blood microfluidic testing. A single
patient (#31) was transfused with 14 units of blood products within 12 hrs of arrival. Microfluidic
testing of this patient detected decreased platelet function upon initial presentation and continuous
attenuated platelet function up to 72 hours post admission (Supplemental Figure S11).

Important distinctions exist between assays that evaluate platelets under non-flow conditions and
microfluidics that allow platelets to accumulate on a surface to levels >200-fold that of whole
blood levels. We demonstrated that microfluidic assay of trauma patient samples is a global test
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of whole blood clotting function under flow with the capability of detecting platelet dysfunction.
In future work, a comparison of microfluidic assay with platelet aggregometry or platelet mappingTEG may provide further insights into platelet dysfunction during TIC. Microfluidic assay allows
determination of: (1) platelet recruitment to the collagen surface, (2) total platelet accumulation,
(3) platelet accumulation rate, and (4) time to full channel occlusion. These metrics could be
compared to platelet mapping-TEG metrics such as maximum clot strength (MAThrombin), the
contribution of ADP receptors (MAADP), and the contribution of the arachidonic acid pathway
(MAAA). For example, we previously observed a relationship between aPTT and platelet
accumulation rates on collagen surfaces for hemophilic blood from patients with increase bleeding
risks (10). Finally, while all trauma patient samples were collected within one hour of injury.
Further validation in the whole blood microfluidic assay is required to examine how a variation in
time of sample collection within the one hour time window affects platelet function under flow as
derangements in trauma patient platelet function is thought to occur rapidly prior to hospital
admissions.

The high throughput nature of microfluidic whole blood testing however, will enable testing of
fresh platelets, stored platelets, and other current and novel drugs used to restore platelet function
during the acute phase of trauma coagulopathy. In a previous study, we have shown a novel method
to assess the incorporation of culture-derived platelets from human peripheral blood cells into
developing human thrombi under flow (28). Using similar techniques, future studies should test
whether stored platelets can incorporate into trauma patient thrombi under flow. Successful
adherence and incorporation of stored platelets into patient thrombi formed ex vivo would indicate
the high potential of these platelets to restore platelet function in acute traumatic coagulopathy.
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The mechanisms underlying trauma platelet dysfunction have yet to be elucidated and require
further investigation outside of microfluidic testing. Groups have postulated that platelet function
downregulation can occur during trauma. Previous studies suggest the presence of dysfunctional
circulating platelets following activation in response to tissue damage (5,7). Platelet receptor
proteolysis may be another putative pathway in which platelet function is down-regulated in
trauma patients. Previous reports describe proteolysis of platelet GPVI and GPIb-IX-V receptors
(29,30). Ectodomain shedding of platelet adhesion receptors is a plausible physiologic mechanism
in which platelets can respond to cases of severe endothelial injury following trauma yet prevent
uncontrolled thrombus growth that leads to systemic clotting.

In this study, we have used microfluidic technology to effectively evaluate current resuscitation
strategies and hyperfibrinolysis showing more rapid detection of impaired hemostasis and
coagulation than what is capable with current technologies. Furthermore, we also tested trauma
patient platelet function using this high throughput method. The fast identification of platelet
function defects in trauma patients using whole blood microfluidic assays indicate a potential novel
15 min test to help guide coagulopathy treatments in the future.
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FIGURE & TABLE LEGENDS

Figure 1. Platelet accumulation on collagen in healthy donors following Hct dilution in the
absence of thrombin
(A & B), Platelet and fibrin fluorescence intensities vs. time with saline dilution of Hct. (C & D),
Platelet and fibrin fluorescence vs. time with PPP dilution of Hct. (E & F), Platelet and fibrin
fluorescence intensities vs. time with PRP dilution of Hct. Shaded traces are the mean and standard
deviation of 10 clotting events from 5 donors.

Figure 2. Platelet and fibrin accumulation on TF-bearing collagen in healthy donors
following Hct dilution
(A & B), Platelet and fibrin fluorescence intensities vs. time with saline dilution of Hct. (C & D),
Platelet and fibrin fluorescence intensities vs. time with PPP dilution of Hct. (E & F), Platelet and
fibrin fluorescence intensities vs. time with PRP dilution of Hct. Shaded traces are the mean and
standard deviation of 10 clotting events from 5 donors.

Figure 3. Platelet and fibrin accumulation in response to exogenous tPA ± εACA at venous
shear rates.
(A), Overlay of platelets (red) and fluorescent fibrinogen (yellow) deposition at 200 s-1 over the
time course of the 20 min assay. (B), Platelet fluorescence intensities vs. time with exogenous tPA
± εACA. (C), Fibrin fluorescence intensities vs. time with exogenous tPA ± εACA. Shaded traces
are the mean and standard deviation of 12 clotting events from 3 donors.
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Figure 4. Platelet and fibrin accumulation in response to exogenous tPA ± εACA at arterial
shear rates.
(A), Overlay of platelets (red) and fluorescent fibrinogen (yellow) deposition at 1222 s-1 over the
time course of the 20 min assay. (B), Platelet fluorescence intensities vs. time with exogenous tPA
± εACA. (C), Fibrin fluorescence intensities vs. time with exogenous tPA ± εACA. Shaded traces
are the mean and standard deviation of 8 clotting events from 2 donors.

Figure 5. Trauma patient thrombi morphology at 900 sec and platelet deposition dynamics
at venous shear rates (100 s-1)
(A & A'), Platelet fluorescence intensities vs. time for representative healthy donor and
representative image of final platelet accumulation at 900 sec. (B-N & B'-N', blue line), Platelet
fluorescence intensities vs. time and representative image of final platelet accumulation at 900 sec
for trauma patients exhibiting loss of platelet function. (O-Q & O'-Q', yellow line), Platelet
fluorescence intensities vs. time and representative images of final platelet accumulation at 900
sec for trauma patients exhibiting normal platelet function. (R-T & R'-T', green line), Platelet
fluorescence intensities vs. time and representative images of final platelet accumulation at 900
sec for trauma patients exhibiting gain of platelet function. Shaded traces are the mean and standard
deviation of 4 clotting evens from each patient. (MCC: Motorcycle Crash, MVC: Motor Vehicle
Crash, SW: Stab wound, GSW: Gun Shot Wound)
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Table 1. Trauma patient characteristics and clinical data.
20 trauma patients were examined in microfluidic assays with PPACK-inhibited whole blood
perfusion over collagen. Medications altering coagulation, blood product use, pre-existing
conditions, Hct, platelet count, Injury Severity Score, diagnosis of traumatic brain injury, PT, PTT,
INR, blood alcohol level, and blood products post microfluidic testing are as reported.
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TABLES

Table 1. 20 trauma patients were examined in microfluidic assays with PPACK-inhibited whole
blood perfusion over collagen. Trauma patient characteristics and clinical data are as reported,
blood products post microfluidic testing were administered within the first hour of evaluation by
Hospital of University of Pennsylvania (HUP) Level 1 Trauma Center.

